Using Technology in Behavioral Approaches to Alzheimer's Disease

1996 ◽  
Vol 8 (S1) ◽  
pp. 67-71 ◽  
Author(s):  
Douglas Holmes ◽  
Jeanne Teresi
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Strategic Planning ◽  
Research Design ◽  
Information Transfer ◽  
Tactical Planning ◽  
Implementation And Dissemination ◽  
Technological Developments ◽  
Made In

Current approaches to the behaviorally based treatment and management of Alzheimer's disease (AD) often fail to take advantage of technological developments in related fields. Thus, there are instances in which the need is not to discover new behavioral approaches, but to make use of “discoveries” made in other fields, charting a course for their application in dealing with AD. This assertion is suggested as a basis for strategic planning involving information transfer, to be conducted in addition to tactical planning regarding research design, implementation, and dissemination.

scholarly journals Imaging and Molecular Mechanisms of Alzheimer’s Disease: A Review

2018 ◽  
Vol 19 (12) ◽  
pp. 3702 ◽  
Author(s):  
Grazia Femminella ◽  
Tony Thayanandan ◽  
Valeria Calsolaro ◽  
Klara Komici ◽  
Giuseppe Rengo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multimodal Imaging ◽  
Molecular Mechanisms ◽  
Imaging Techniques ◽  
Structural Mri ◽  
Imaging Biomarkers ◽  
Significant Burden ◽  
Made In

Alzheimer’s disease is the most common form of dementia and is a significant burden for affected patients, carers, and health systems. Great advances have been made in understanding its pathophysiology, to a point that we are moving from a purely clinical diagnosis to a biological one based on the use of biomarkers. Among those, imaging biomarkers are invaluable in Alzheimer’s, as they provide an in vivo window to the pathological processes occurring in Alzheimer’s brain. While some imaging techniques are still under evaluation in the research setting, some have reached widespread clinical use. In this review, we provide an overview of the most commonly used imaging biomarkers in Alzheimer’s disease, from molecular PET imaging to structural MRI, emphasising the concept that multimodal imaging would likely prove to be the optimal tool in the future of Alzheimer’s research and clinical practice.

Time for a New Strategy in the War on Alzheimer’s Disease

2019 ◽  
Vol 29 (4) ◽  
pp. 119-122
Author(s):  
Matt Kaeberlein
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Mechanisms ◽  
Well Being ◽  
Developed Countries ◽  
Biological Aging ◽  
Root Cause ◽  
New Strategy ◽  
New Strategies ◽  
Made In

Abstract Alzheimer’s disease is a growing threat to the economic and social well-being of developed countries around the globe, but efforts to delay, prevent, or cure this disorder have yet to yield success. I believe the lack of progress largely results from approaches that ignore the most important component of Alzheimer’s disease: biological aging. Major advances have been made in understanding the molecular mechanisms that link biological aging to disease. These mechanisms have been formalized as nine hallmarks, or pillars, of aging. Here, I discuss the barriers that have impaired progress and propose specific steps that can be taken to overcome these barriers. The time has come to adopt bold new strategies that tackle biological aging as the root cause of Alzheimer’s disease.

scholarly journals Social support as a mediator variable of the relationship between depression and life satisfaction in a sample of Saudi caregivers of patients with Alzheimer's disease

2017 ◽  
Vol 29 (6) ◽  
pp. 1053-1053 ◽  
Author(s):  
Shatha Jamil Khusaifan ◽  
Mogeda El Sayed El Keshky
Keyword(s):  
Social Support ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Life Satisfaction ◽  
Financial Support ◽  
Scientific Research ◽  
King Abdulaziz University ◽  
The Relationship ◽  
Mediator Variable ◽  
Made In

The authors would like to apologise for an error made in the acknowledgement of the above mentioned article.In the acknowledgement section of the article, paragraph ‘This project was funded by the Deanship of Scientific Research (DSR), at King Abdulaziz University, Jeddah, under grant no. (G-282/ 724246/1436). The authors, therefore, acknowledge with thanks DSR for technical and financial support’.Should read:This project was funded by the Deanship of Scientific Research (DSR), at King Abdulaziz University, Jeddah, under grant no. (G-282-246-36). The authors, therefore, acknowledge with thanks DSR for technical and financial support’.

scholarly journals The GAB2 and BDNF polymorphisms and the risk for late-onset Alzheimer's disease in an elderly Brazilian sample – ERRATUM

2015 ◽  
Vol 27 (10) ◽  
pp. 1693-1693
Author(s):  
Renalice Neves Vieira ◽  
Joalce Dornelas Magalhães ◽  
Jemima Sant’Anna ◽  
Mateus Massao Moriguti ◽  
Débora Marques de Miranda ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Late Onset ◽  
Correct Order ◽  
Brazilian Sample ◽  
Made In

In the above mentioned article by Vieira et al., an error has been made in the order of which the authors appear. The correct order is stated below:Renalice Neves Vieira, Joalce Dornelas Magalhães, Jemima Sant’Anna, Mateus Massao Moriguti, Jonas Jardim de Paula, Marco Túlio Gualberto Cintra, Débora Marques de Miranda, Luiz De Marco, Edgar Nunes de Moraes, Marco Aurélio Romano-Silva, Maria Aparecida Camargos Bicalho.

scholarly journals Alzheimer’s disease as the cerebral cortex disorder

2019 ◽  
Vol 4 (2) ◽  
pp. 16-20
Author(s):  
Volobuev AN ◽  
Romanchuk PI ◽  
Bulgakova SV
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Information Transfer ◽  
Brain Cortex ◽  
Senile Dementia ◽  
Memory Storage ◽  
Neuronal Circuits ◽  
Storage Element ◽  
Dementia Of Alzheimer’S Type ◽  
The Brain

Objectives – to highlight the structure, function and localization of Alzheimer’s disease and to specify cognitive impairments related to it. Material and methods. The anatomic data of human brain structure were used. Results. The patterns of memory formation in the brain cortex are investigated. The brain cortex is presented as a type of syncytium consisting of elementary neural structures – cyclic neuronal circuits – memory elements. All cyclic neuronal circuits in a brain cortex are functionally interconnected. The connections between the neuronal circuits can be determined (imprinted) and stochastic (random). The intensity of stochastic communications defines the person's potential for creativity. The impairment of cyclic neuronal circuit connections results in either Alzheimer’s disease or in senile dementia of Alzheimer’s type. Conclusion. In case the cortex is considered as the syncytium, the memory storage element, it can be the reason of the human creativity. It is shown that the failure of the information transfer in the cortex syncytium or neurons destruction in the neuronal network results in Alzheimer’s disease or in senile dementia of Alzheimer’s type.

scholarly journals Alzheimer’s Disease and Diabetes Mellitus in Comparison: The Therapeutic Efficacy of the Vanadium Compound

2021 ◽  
Vol 22 (21) ◽  
pp. 11931
Author(s):  
Zhijun He ◽  
Guanying You ◽  
Qiong Liu ◽  
Nan Li
Keyword(s):  
Diabetes Mellitus ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Spatial Learning And Memory ◽  
Therapeutic Effects ◽  
Vanadium Compound ◽  
The Us ◽  
Effective Drugs ◽  
Amyloid Cascade ◽  
Made In

Alzheimer’s disease (AD) is an intractable neurodegenerative disease that leads to dementia, primarily in elderly people. The neurotoxicity of amyloid-beta (Aβ) and tau protein has been demonstrated over the last two decades. In line with these findings, several etiological hypotheses of AD have been proposed, including the amyloid cascade hypothesis, the oxidative stress hypothesis, the inflammatory hypothesis, the cholinergic hypothesis, et al. In the meantime, great efforts had been made in developing effective drugs for AD. However, the clinical efficacy of the drugs that were approved by the US Food and Drug Association (FDA) to date were determined only mild/moderate. We recently adopted a vanadium compound bis(ethylmaltolato)-oxidovanadium (IV) (BEOV), which was originally used for curing diabetes mellitus (DM), to treat AD in a mouse model. It was shown that BEOV effectively reduced the Aβ level, ameliorated the inflammation in brains of the AD mice, and improved the spatial learning and memory activities of the AD mice. These finding encouraged us to further examine the mechanisms underlying the therapeutic effects of BEOV in AD. In this review, we summarized the achievement of vanadium compounds in medical studies and investigated the prospect of BEOV in AD and DM treatment.

scholarly journals Non-Invasive Diagnostic Biomarkers for Alzheimer’s Disease

2021 ◽  
Vol 3 (1) ◽  
pp. 12-18
Author(s):  
Shyamasri Biswas ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Stage ◽  
Clinical Success ◽  
Potential Game ◽  
Diagnostic Biomarkers ◽  
Non Invasive ◽  
Presymptomatic Stage ◽  
The Subject ◽  
Made In

The emergence of biomarkers in biologic fluids is considered an important milestone in the field of Alzheimer’s disease (AD) research. Biomarkers are widely considered critically important for the diagnosis and therapeutic intervention of the disease. It is believed that an early diagnosis of AD at a presymptomatic stage could provide the key for a successful intervention and treatment of AD. It is due to the reason that preventative and therapeutic strategies that are known to be AD stage-dependent can have a better chance of clinical success at a very early stage of the disease when critical neurons are not lost. To this end, current clinical trials are extensively being employed by taking advantage of different diagnostic biomarkers. While there has been notable progress in biomarkers for AD, the current research emphasis has been on exploring non-invasive biomarkers due to the advantages of cost-effectiveness, rapid diagnosis and significantly less medical procedural complexities that make these biomarkers potential game changer in AD diagnostics. Here, we present a bird eye view on the subject and discuss the progress made in important non-invasive biomarkers for AD.

scholarly journals Naturally Inspired Pyrimidines Analogues for Alzheimer’s Disease

2020 ◽  
Vol 19 (2) ◽  
pp. 136-151
Author(s):  
Shivani Singh ◽  
Meenakshi Dhanawat ◽  
Sumeet Gupta ◽  
Deepak Kumar ◽  
Saloni Kakkar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multicomponent Reactions ◽  
Neurodegenerative Disorder ◽  
The Body ◽  
New Drugs ◽  
Atom Economy ◽  
Step Process ◽  
One Step ◽  
Made In

: Alzheimer’s disease (AD) is a multifarious and developing neurodegenerative disorder. The treatment of AD is still a challenge and availability of drug therapy on the basis of symptoms is not up to the mark. In the context of existence, which is getting worse for the human brain, it is necessary to take care of all critical measures. The disease is caused due to multidirectional pathology of the body, which demands the multi-target-directed ligand (MTDL) approach. This gives hope for new drugs for AD, summarized here in with the pyrimidine based natural product inspired molecule as a lead. The review is sufficient in providing a list of chemical ingredients of the plant to cure AD and screen them against various potential targets of AD. The synthesis of a highly functionalized scaffold in one step in a single pot without isolating the intermediate is a challenging task. In few examples, we have highlighted the importance of this kind of reaction, generally known as multi-component reaction. Multi-component is a widely accepted technique by the drug discovery people due to its high atom economy. It reduces multi-step process to a one-step process, therefore the compounds library can be made in minimum time and cost. This review has highlighted the importance of multicomponent reactions by giving the example of active scaffolds of pyrimidine/fused pyrimidines. This would bring importance to the fast as well as smart synthesis of bio-relevant molecules.

Recent Advances in Synaptosomal Proteomics in Alzheimer’s Disease

2021 ◽  
Vol 22 ◽  
Author(s):  
Faraz Ahmad ◽  
Shafiul Haque ◽  
Vishal Chavda ◽  
Ghulam Md Ashraf
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neurodegenerative Disorders ◽  
Meta Analysis ◽  
Subcellular Fractionation ◽  
Synaptic Physiology ◽  
Brain Functions ◽  
Chemical Synapses ◽  
Molecular Signals ◽  
Made In

: The current meta-analysis of the cohort review was designed to elucidate the progress made in neuroproteomics of the synaptosome. The association of the comprehensive synaptic proteome and its link to physiological or pathological settings is rapidly mounting. Chemical synapses in the brain are focal hot spots for interneuronal signaling, signal transduction, and plasticity. Structurally, synapses comprise axon termini or the presynapse (vesicles filled with neurotransmitters that function as molecular signals), synaptic clefts (extracellular matrix and adhesion molecules), and post-synaptic density or PSD (with receptors for neurotransmitters that rely upon the chemical signaling). The pre- and post-synaptic clefts are responsible for mediating and regulating neurotransmitter release Their receptor binding and perception rely on chemical signals. Moreover, short- and long-term structural and functional alterations that are necessary for the optimal higher-order brain functions are also mainly dependent on the protein dynamics at the synapses. Not surprisingly, disruptions in synaptic physiology are considered as the major pathogenic mechanisms underlying the progression of several neurodegenerative disorders, including Alzheimer's disease. This review briefly discusses the subcellular fractionation protocols and the related biochemical approaches for the isolation of synaptic compartments. Besides, it discusses the progress made in understanding the pathological alterations in the synaptic proteome in neurodegenerative disorders, particularly focussing on Alzheimer's disease dementia.

Is targeting beta-amyloid pathology, with immunotherapy, an effective treatment option for Alzheimer's disease?

2011 ◽  
Vol 21 (4) ◽  
pp. 340-345 ◽  
Author(s):  
James O'Donovan
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Effective Treatment ◽  
Critical Appraisal ◽  
Effective Treatment Option ◽  
Potential Form ◽  
Amyloid Aβ ◽  
Β Amyloid ◽  
Disease Modifying ◽  
Made In

SummaryAlzheimer's disease (AD) is the commonest form of dementia, estimated to affect 37 million people worldwide. Currently there is nothing to halt the progression of AD – treatment focuses largely on slowing the development of symptoms. More recently disease-modifying interventions, such as immunotherapy, have been investigated as their aim is to halt or even reverse symptoms by removing β-amyloid (Aβ) pathology. This paper assesses the developments made in this particular field, offers critical appraisal of important papers and assesses the viability of this potential form of treatment.

Sign in / Sign up

Export Citation Format

Share Document